Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
26-06-12	0.4860 kr	+6.23%	681,022
26-06-11	0.4575 kr	+3.62%	592,487
26-06-10	0.4415 kr	-3.92%	1,521,143
26-06-09	0.4595 kr	-0.11%	4,486,313
26-06-08	0.4600 kr	+3.14%	740,111

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2026-06-12 EDT			5-day change	1st Jan Change
0.4860 ^SEK	+6.23%		+8.97%	-41.38%

06-12	Alzinova raises SEK15.3m from warrants: underwriting not required	FW
06-08	Alzinova raises SEK 15.2 million before issuance costs	FW

Market Cap	75.31M 7.98M 6.89M 6.35M 5.96M 11.16M 759M 11.32M 29.28M 369M 29.95M 29.31M 1.29B	P/E Ratio 2026 *	-1.52x	P/E Ratio 2027 *	-0.99x
Enterprise Value	72.31M 7.66M 6.62M 6.1M 5.72M 10.71M 729M 10.87M 28.11M 354M 28.76M 28.14M 1.24B	EV / Sales 2026 *	2.31x	EV / Sales 2027 *	-
Free-Float	82.23%	Yield 2026 *	-	Yield 2027 *	-

06-12	Alzinova raises SEK15.3m from warrants: underwriting not required	FW
06-08	Alzinova raises SEK 15.2 million before issuance costs	FW
05-26	Calendar Tuesday May 26	FW
05-25	Calendar Tuesday May 26	FW
05-21	Alzinova secures 80 percent of TO4 warrants	FW
05-20	Alzinova phase 1b results published in scientific journal	FW
05-20	Alzinova AB Publishes Clinical Results with ALZ-101 in Alzheimer?s Research & Therapy	CI
05-13	Alzinova AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-13	Alzinova Q1 loss after financial items SEK 6 mln	RE
05-13	Alzinova reports narrowed operating loss - CEO: we see rapidly growing commercial interest in diagnostics	FW
05-11	Alzinova article on Alzheimer's vaccine published in scientific journal	FW
05-11	Alzinova AB Announces Clinical Results with Alz-101 to Be Published in Scientific Journal	CI
05-05	Eight stocks hit new 52-week lows on the Stockholm Stock Exchange so far today	FW

04-08	RX Securities sees potential upside for Alzinova from Alzheimer's diagnostic collaboration	FW
03-26	DNB Carnegie sees reduced financing risk for Alzinova, but partnership remains critical	FW
25-10-06	Alzinova gets fast track designation from US FDA	RE
25-10-05	Alzinova's Alzheimer's Disease Vaccine Candidate Gets Fast-track Designation from US FDA	MT
25-10-04	Alzinova AB Receives Fast Track Designation from US FDA for ALZ-101 in Alzheimer's Disease	CI

Alzinova AB Stock

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation: Alzinova AB

Chart: Alzinova AB

Latest news : Alzinova AB

Analysts' recommendations: Alzinova AB

Press Releases: Alzinova AB

Quotes and Performance

Course Extremes

Managers and Directors: Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

06-12	Warrants of series TO4 were exercised to approximately 94.2 percent and the Company will receive approximately 15.3 million	AQ
06-08	Alzinova announces preliminary outcome of the exercise of warrants of series TO4	AQ
06-03	The last day of trading with the warrants of series TO4 in Alzinova is today, June 3, 2026	AQ
05-26	Bulletin from the Annual General Meeting of Alzinova AB (publ)	AQ
05-25	The subscription price for warrants of series TO4 in Alzinova has been determined to SEK 0.32 and the exercise period begins today	AQ

1 day	+6.23%
1 week	+8.97%
Current month	+12.89%
1 month	+20.00%
3 months	-33.42%
6 months	-70.37%
Current year	-41.38%

1 week	0.44	0.58
1 month	0.41	0.58
Current year	0.38	0.97
1 year	0.38	2.28
3 years	0.38	4.62
5 years	0.38	9.35
10 years	0.38	44.9

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	2024-09-30
Anders Sandberg COO	Chief Operating Officer	54	2011-08-16
Erik Kullgren DFI	Director of Finance/CFO	57	2024-03-26

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	2015-08-31
Anders Waas BRD	Director/Board Member	69	2017-12-31
Carol Routledge BRD	Director/Board Member	-	2017-12-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	+6.23%	+8.97%	-71.48%	-84.35%	8.01M
LONZA GROUP AG	-0.35%	+0.97%	-15.96%	-12.73%	43.03B
REVOLUTION MEDICINES, INC.	+3.11%	+3.11%	+274.29%	+507.94%	32.71B
IQVIA HOLDINGS INC.	+0.22%	-1.08%	+14.03%	-14.37%	30.29B
BEONE MEDICINES AG	+1.62%	-2.08%	-4.36%	+24.05%	29.4B
CELLTRION, INC.	+4.09%	+0.93%	+10.83%	+18.78%	25.08B
MEDPACE HOLDINGS, INC.	-1.63%	+2.88%	+53.73%	+114.36%	13.35B
ASCENDIS PHARMA A/S	+1.14%	+3.62%	-	-	13.54B
EUROFINS SCIENTIFIC SE	-0.40%	-1.29%	+6.06%	+7.59%	12.97B
IONIS PHARMACEUTICALS, INC.	-0.74%	-1.62%	+105.71%	+76.01%	12.11B
Average	+1.33%	+2.20%	+41.43%	+70.81%	21.25B
Weighted average by Cap.	+1.05%	+1.48%	+54.94%	+97.30%

	2026 *	2027 *
Net sales	31.35M 3.32M 2.87M 2.64M 2.48M 4.64M 316M 4.71M 12.19M 154M 12.47M 12.2M 536M	-
Net income	-3.2M -339K -293K -270K -253K -474K -32.25M -481K -1.24M -15.68M -1.27M -1.25M -54.73M	-50.35M -5.34M -4.61M -4.25M -3.98M -7.46M -507M -7.57M -19.57M -247M -20.02M -19.6M -861M
Net Debt	-3M -318K -275K -253K -237K -444K -30.23M -451K -1.17M -14.7M -1.19M -1.17M -51.31M	-7M -742K -641K -591K -554K -1.04M -70.54M -1.05M -2.72M -34.31M -2.78M -2.72M -120M